Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 3/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 1/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 10/20 | 0.56 |
| ▸ | TSHR | P16473 | 7/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30150607 | 0.91 | PTGER2 (0.84) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL30150602 | 0.91 | PTGER2 (0.84) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL2435853 | 0.90 | PTGER2 (0.82) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL24817542 | 0.90 | PTGER4 (0.81) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL24817294 | 0.90 | PTGER2 (0.81) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL30925661 | 0.90 | PTGER2 (0.81) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL24817248 | 0.89 | PTGER2 (0.80) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL2435176 | 0.89 | PTGER4 (0.80) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL24817251 | 0.89 | PTGER2 (0.80) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 | |
| SCHEMBL24817250 | 0.89 | PTGER2 (0.80) | PTGER2PTGER4PTGDRCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | claimed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | claimed |
| US-20250188026-A1 | EP2 Antagonist Compounds | RESERVOIR NEUROSCIENCE, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250161446-A1 | MODIFIED IMMUNE CELLS FOR TREATING AND/OR PREVENTING METASTASIS | Technische Universität München (DE) | 2025-05-22 | — | — | US | disclosed |
| US-12297171-B2 | EP2 antagonist compounds | RESERVOIR NEUROSCIENCE, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| EP-4486869-A1 | MODIFIED IMMUNE CELLS FOR TREATING AND/OR PREVENTING METASTASIS | Technische Universität München (DE) | 2025-01-08 | — | — | EP | disclosed |
| US-20240182411-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| EP-4359399-A1 | EP2 ANTAGONIST COMPOUNDS | Reservoir Neuroscience, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2023161498-A1 | MODIFIED IMMUNE CELLS FOR TREATING AND/OR PREVENTING METASTASIS | Technische Universität München (DE) | 2023-08-31 | — | — | WO | disclosed |
| WO-2022272062-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272062-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278343-B2 | Pyrrolidines | PFIZER INC. (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120793-A1 | Pyrrolidines | PFIZER ANIMAL HEALTH UK 1 LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120793-A1 | Pyrrolidines | PTGER2, PTGDR2, PTGES2 | PTGER2 1/4885PTGER4 11/4885PTGDR 10/4885 |
| US-20250188026-A1 | EP2 Antagonist Compounds | PTGER2, PTGER1, PTGES2 | PTGER2 1/4885PTGER4 5/4885PTGDR 10/4885 |
| US-12297171-B2 | EP2 antagonist compounds | PTGER2, PTGER1, PTGES2 | PTGER2 1/4885PTGER4 5/4885PTGDR 10/4885 |
| US-20240182411-A1 | EP2 ANTAGONIST COMPOUNDS | PTGER2, PTGER1, PTGES2 | PTGER2 1/4885PTGER4 5/4885PTGDR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.